Modalis announces partnership with ginkgo bioworks

Tokyo & waltham, mass.--(business wire)--modalis therapeutics corporation (modalis) (tokyo stock exchange: 4883) announced that it has entered into an agreement with ginkgo bioworks (ginkgo) to join the ginkgo technology network. this strategic alliance will enable ginkgo's global customers in the cell and gene therapy fields to access modalis' proprietary epigenome modulation technology, crispr-gndm® (guide nucleotide-directed modulation). modalis' crispr-gndm® technology is capable of activat.
DNA Ratings Summary
DNA Quant Ranking